目前分類:出國留學體檢 (12)

瀏覽方式: 標題列表 簡短摘要

 

Interferon-Gamma Release Assays (IGRAs)

Interferon-Gamma Release Assays (IGRAs) are whole-blood tests that can aid in diagnosing Mycobacterium tuberculosis infection. They do not help differentiate latent tuberculosis infection (LTBI) from tuberculosis disease. Two IGRAs that have been approved by the U.S. Food and Drug Administration (FDA) are commercially available in the U.S:

  • QuantiFERON®-TB Gold In-Tube test (QFT-GIT); (本診所提供該項檢驗)
  • T-SPOT®.TB test (T-Spot)

 

http://www.cdc.gov/tb/publications/factsheets/testing/igra.htm

請聯絡:(03) 573-5050,新竹清華診所。(清大夜市內)

 

出國留學體檢,Tuberculosis,blood test,PPD skin test,台灣新竹

肺結核驗血

 

 

Updated Guidelines for Using Interferon Gamma Release Assays
to Detect Mycobacterium tuberculosis Infection — United States, 2010

清華診所的臉書facebook:

https://www.facebook.com/FamilyDoctors
https://zh-tw.facebook.com/FamilyDoctors

 

 

airtsuei 發表在 痞客邦 PIXNET 留言(0) 人氣()

 本診所提供 QuantiFERON , Tuberculosis Skin Test ( 結核菌素測驗, PPD Skin Test, Tuberculin Skin Test), 胸部X光檢查 (chest x-ray)

新竹清華診所為新竹專門提供出國留學、遊學體檢的診所。電話:(03) 573 5050。歡迎出國學子先來電詢問。

 

T‑SPOT.TB is a revolutionary in vitro diagnostic test that measures T cells specific to Mycobacterium tuberculosis (MTB) antigens. Based on the pioneering T-SPOT technology, it was developed for diagnosing both latent TB infection and TB disease in humans.    T-SPOT.TB sets new clinical standards of sensitivity and reliability, even in the immunocompromised. The product was licensed in the European Union in July 2004, received FDA premarket approval in July 2008 and is expected to replace the current tuberculin skin test, bringing effective TB testing to many new patient groups where the skin test gives poor results.

This revolutionary technology has been described in a significant number of peer-reviewed publications which highlight the tests excellent performance in a wide range of clinical and epidemiological settings (see clinical information) . These studies confirm the excellent sensitivity and specificity of T‑SPOT.TB and demonstrate its utility for the diagnosis and control of TB around the world, especially for latent TB in the developed world.

The test offers hope at a time when TB has re-emerged as a major global health threat. Nearly one third of the world's population is infected with MTB. Nine million people develop active disease every year and TB kills an estimated 2-3 million people each year (one person every 15 seconds). The huge toll of TB on human life prompted the World Health Organisation to declare TB a "global emergency" in 1993.

T‑SPOT.TB offers:

Unrivalled clinical performance
Simple and robust laboratory performance
Saves costs in TB control

 

Unrivalled clinical performance

  • Very few false negative results (sensitivity ~95%)
    • Improving reliable detection of truly infected individuals
  • No patient exclusions
    • Can be used in HIV, very young children,anti-TNF α, transplant, renal dialysis, malnourished and other immunocompromised patient groups, as well as in pregnancy

  • Virtually eliminates potentially toxic chemoprophylaxis due to false positive results 
    • Unaffected by BCG vaccination and common non-tuberculous mycobacteria

Simple and robust laboratory performance

  • Virtually no repeat testing (due to low frequency of indeterminates)
  • Results next day
  • No need for patient return visit

Saves costs in TB Control

  • Minimises costs associated with onward transmission
  • Virtually eliminates unnecessary treatment & monitoring costs
  • T-SPOT.TB-based screening strategies are significantly cost-saving when compared to the status quo of TST-based TB control programmes1
  • The use of T-SPOT.TB greatly reduces the number of contacts treated to prevent one TB case1

1Diel R, et al. ERJ 2007 30: 321-332

 

清華診所的臉書facebook:

https://www.facebook.com/FamilyDoctors

https://zh-tw.facebook.com/FamilyDoctors

airtsuei 發表在 痞客邦 PIXNET 留言(0) 人氣()

新竹清華診所為新竹專門提供出國留學、遊學體檢的診所。電話:(03) 573 5050。歡迎出國學子先來電詢問。

 

A. 疫苗接種:

     1. Tetanus, diphtheria, and acellular pertussis (Tdap) ;
         tetanus, diphtheria (Td)

     2. Varicella

     3. Measles, mumps, rubella (MMR)

     4. Meningococcal *

     5. Hepatitis B

     6. Hepatitis A

     7. Human papillomavirus (HPV)

 

B. PPD skin test (Tuberculosis skin tes, tuberculin skin test, 結核菌素測驗)

C. QuantiFERON-TB Gold; QuantiFERON-TB Gold In-Tube.

D.  Chest x-ray (胸部X光檢查)

E: 驗血

F: 驗尿

 

 

清華診所的臉書facebook:

https://www.facebook.com/FamilyDoctors

https://zh-tw.facebook.com/FamilyDoctors

 

《新竹市小兒科診所、新竹小兒科診所、新竹小兒科、家庭醫學科診所、內科 診所、新竹診所推薦、新竹市小兒科推薦 、新竹小兒科推薦、新竹家庭醫師推薦、美國留學體檢 、加拿大留學體檢、英國留學體檢、澳洲留學體檢、留學體檢推薦、清大夜市診所、清大宵夜街診所、清夜診所、清大小吃、 兒童心理諮商、個人心理諮商、》

 

airtsuei 發表在 痞客邦 PIXNET 留言(0) 人氣()

本診所提供  QuantiFERON , Tuberculosis Skin Test ( 結核菌素測驗, PPD Skin Test, Tuberculin Skin Test), 胸部X光檢查 (chest x-ray)

 

新竹清華診所為新竹專門提供出國留學體檢的診所。電話:(03) 573 5050。歡迎出國學子先來電詢問。美國留學體檢推薦診所。

Q:留學體檢需要什麼資料?

A:最常需要的就是記錄預防接種的黃卡。

留學體檢包括三大部份:

〈1〉檢驗:驗血/驗尿/結核菌素皮膚試驗、

〈2〉預防接種、

〈3〉身體檢查。

另外體檢表格有一部份不屬於醫師填寫的部份,這一部份需要學生自己完成。通常包括:過往的疾病史、是否有過敏性疾病、有那些藥物、食物過敏、目前服用什麼藥物、、、等等有關個人的健康資料。如果看不懂時,請携帶著,到時一 起詢問醫師。

預防接種記錄的黃卡上,會詳細地記錄你以前小時侯所接種的疫苗。應該說,記錄你入小學之前所有的預防接種記錄。至於入小學後的記錄有時無法記錄在黃卡上,事隔多年要再找,實在很難。

如果實在找不到黃卡,可以試試當地的衛生所,說不一定他們會保存以前預防接種的記錄。如果實在都找不到黃卡、衛生所也沒有記錄,只好跟醫師研究一下,看看如何補救。

註:記錄預防接種的黃卡現在已不在使用。現在新生兒出院時,醫院都會給父母親一本小冊子。這本小冊子叫「兒童健康手冊」,由衛生署國民健康局印行。裡面包括一些有關新生兒/幼兒健康衛生知識,及健康記錄,其中包括了預防接種記錄卡。所以,請謹慎保管這本小冊子。

不過,這幾年台灣預防接種做的非常好,其中一部份就是接種記錄的登錄與保存。但是時間較久遠前的資料,可能就不一定。

 

清華診所的臉書facebook:
https://zh-tw.facebook.com/FamilyDoctors
https://www.facebook.com/FamilyDoctors

airtsuei 發表在 痞客邦 PIXNET 留言(0) 人氣()

新竹清華診所為新竹專門提供出國留學體檢的診所。電話:(03) 573 5050。歡迎出國學子先來電詢問。美國留學體檢推薦診所。

Q:何時開始做準備留學體檢?

A:通常收到學校入學許可的套件內都會有入學必須填寫的資料,當然攸關留學體檢的表格也一併在內。

體檢表格內容,可以簡單地只有一、二頁,也可以複雜地多到十幾頁,更不用說裡面寫了一大堆看不懂的醫學名詞。

 

通常體檢表格包括:〈1〉驗血〈2〉預防接種〈3〉身體檢查。

醫師會先過目體檢表格,決定是否要驗血?那些疫苗要打?去那裡打?疫苗打的順序?這些可能會需要幾天,甚至幾週的時間。所以,最好是收到體檢表格後,儘快與醫師聯絡,以免時間太倉促。


最常見的處理方式就是拿去請教有經驗的朋友或同學,但最好的處理方式就是請教有關的醫療人員。

 

 

清華診所的臉書facebook:
https://zh-tw.facebook.com/FamilyDoctors
https://www.facebook.com/FamilyDoctors

 

airtsuei 發表在 痞客邦 PIXNET 留言(0) 人氣()

流行性腦脊髓膜炎是由奈瑟氏腦膜炎球菌(Neisseria meningitidis)所引起,它是一種革蘭氏陰性雙球菌。目前已知有十三種血清型(group A、B、C、D、H、I、K、L、X、Y、Z、29E、W-135),其中的A、B、C三型是較容易引起大流行者。

流行性腦脊膜炎是以直接接觸及飛沫為傳染方式,而實際上大部份的人在感染到腦膜炎雙球菌後並沒有臨床症狀出現,卻成為無症狀的帶原者。流行性腦脊髓膜炎最容易發生在小孩及年輕人身上。在感染後約有2-10天的潛伏期,然後以突然發燒,劇烈頭痛為初發病徵,會伴有噁心、嘔吐、頸部僵硬的情形。之後可能出現嗜睡、意識混亂或者癲癇發作。當疾病進行至腦膜炎球菌性敗血症(meningococcal sepsis)時會有休克、及出血性皮膚疹出現。

流行性腦脊髓膜炎的致死率很高,約5%到10%,若未經治療則死亡率更高達50%!而有幸存活的患者則有15%~20%的機會可能留下神經學上的後遺症,如:失聰、智能發展障礙。

由於它的高死亡率,流行性腦脊髓膜炎屬內科急症,抗生素必需在完成腰椎穿刺,取得腦脊髓液及血液的檢體後馬上給予。和患者有過較親密接觸的人員,可給預防性的抗生素(如:Rifampicin 200mg,一天服用兩次,連服兩天)。但當發生大流行時,唯有全面性的施予流行性腦脊髓膜炎疫苗才有辦法緩解疫情。不過,流行性腦脊髓膜炎疫苗是一種四價疫苗,它只能對A、C、Y、W135等四種血清型產生抗體。施打流行性腦脊髓膜炎疫苗後約七天就可開始出現免疫效果,而接種一次約可維持三年的免疫力。需持續具保護力者,應每三年追加一劑。

 

清華診所的臉書facebook:
https://zh-tw.facebook.com/FamilyDoctors
https://www.facebook.com/FamilyDoctors

airtsuei 發表在 痞客邦 PIXNET 留言(0) 人氣()

新竹清華診所為新竹專門提供出國留學體檢的診所。電話:(03) 573 5050。歡迎出國學子先來電詢問。美國留學體檢推薦診所。

流行性腦脊髓膜炎苗 (Meningococcal vaccination)

一、預防疾病:

流行性腦脊髓膜炎(Meningococcal disease),由腦膜炎球菌(Neisseria meningitides)感染引起的細菌性腦膜炎或菌血症。藉由接觸到病人或帶菌者的飛沫或鼻咽部分泌物而感染,潛伏期2-10天(平均3-4天),雖然多數被感染者沒有明顯的症狀,但少數人會進展成嚴重侵襲性的菌血症,若沒有即時給予抗生素治療,得病者的致死率可高達8%-15%。

二、疫苗介紹 :

      1. 流行性腦脊髓膜炎苗(Meningococcal vaccine)有兩大類,包括腦膜炎球菌多糖疫苗(MPSV4)與腦膜炎球菌結合疫苗(MCV4),這兩種疫苗都可以預防4種不同血清型的腦膜炎球菌(A, C, Y, W-135),效果都很好,注射疫苗的人約90%都得到了保護,只是疫苗提供保護的這4種血清型,不一定與某些地區流行的腦膜炎球菌血清型完全相同。

      2. 目前在台灣使用的是注射型的腦膜炎球菌多糖疫苗(MPSV4),適用於2歲以上之族群。Menomune .Mencevax® ACWY - GlaxoSmithKline

三、接種時間表:

      1.2歲以上的兒童或成年人,MPSV4應注射1劑,保護效果至少3年。

      2.在特殊情況下,對於3個月至2歲大的兒童,可以建議使用MPSV4,但應注射2劑,第1劑與第2劑之間相隔3個月。

四、旅遊者接種注意事:

      1.欲前往非洲流行區工作或旅遊者,至少於出發前10天,接種一劑流行性腦脊髓膜炎疫苗。

      2. 留學生出國前10天,也須根據學校相關規定注射一劑流行性腦脊髓膜炎疫苗。

五、副作用 :

      接種部位可能有紅、腫、疼、痛情形,偶有發燒倦怠,通常1-2日即消失。

六、禁忌 :

      1. 發高燒。

      2. 對流行性腦脊髓膜炎疫苗曾發生過敏反應者。

 

註:本表轉載自行政院衛生署疾病管制局。

 

 

流行性腦脊髓膜炎之流行趨勢及疫苗在防疫上的角色 ( 2016-02-23 )


DOI: 10.6524/EB.20160223.32(4).001
陳素幸、王恩慈、蘇韋如、顏哲傑

衛生福利部疾病管制署急性傳染病組
 

2016年2月   第32卷   第4期 通訊作者:陳素幸


摘要:

由奈瑟氏腦膜炎雙球菌所引起的流行性腦脊髓膜炎,在臨床上常以急性嚴重之併發症狀出現如腦膜炎、菌血症及敗血症等,並容易造成後遺症,其最有效之預防方法為施打疫苗,近年來因疫苗的廣泛使用,使得該疾病之發生率已大幅下降。

隨著區域不同,流行型別亦有所差異,近年來,B型血清群腦膜炎球菌(serogroup B meningococcus)已逐漸成為許多國家流行性腦脊髓膜炎最主要之致病原,因此近期研發成功之新型B型疫苗(Bexsero®Trumenba®),在疾病防治上,佔有越來越重要之角色。

我國自2006年至今,每年流行性腦脊髓膜炎發生率均在每十萬人口0.1人以下,相較於歐美先進國家,我國屬於年發生率偏低的國家。雖然我國近年來流行性腦脊髓膜炎確定個案大多數為B型,但個案數少且多為散發性病例,因此在疾病防治上,仍以抗生素治療及預防性投藥為主。

 

附件下載附件下載:

 

 

airtsuei 發表在 痞客邦 PIXNET 留言(0) 人氣()

新竹清華診所為新竹專門提供出國留學體檢的診所。電話:(03) 573 5050。歡迎出國學子先來電詢問。美國留學體檢推薦診所。

Mencevax ACWY

SmithKline Beecham International - Pharmaceuticals [CPI Manufacturer]
Pregnancy Category B2
Use: Active immunisation against meningococcal meningitis

(groups A, C, W[135], Y) in adults, children > 2 years: close
contacts of patients with disease; travellers to epidemic countries;
epidemic control in confined communities

Contraindications: Severe acute febrile illness; IV admin.
Precautions: Impaired immune response; acute malaria;
pregnancy, lactation

Adverse Reactions: Local erythema, induration, pain;
lymphadenopathy; fever; URT illness; malaise; headache;
increased meningococcal carriage rates


Mencevax ACWY (Injection) Rx
Neisseria meningitidis vaccine
Neisseria meningitidis (meningococcus) groups A 50 mcg, C 50
mcg, W[135] 50 mcg and Y 50 mcg (purified polysaccharides)
per 0.5 mL; lyophilised; monodose vial; Gluten free.
Pack(s): 0.5 mL (+ solv.) .Fields[1]: $43.55

Dose: Adults, children > 2 years: 0.5 mL SCI; see MIMS
Annual

Composition
Active.

Each 0.5 mL dose of reconstituted vaccine contains 50
microgram of each of the polysaccharide of groups A, C,
W[135] and Y.

Inactive.
Solvent: isotonic sodium chloride solution.

Description
Mencevax ACWY is a lyophilised preparation of purified
polysaccharides from Neisseria meningitidis (meningococcus)
of groups A, C, W[135] and Y. It is presented as a white pellet
in a glass vial together with a separate vial of clear, colourless,
sterile saline solvent. When reconstituted with the solvent
supplied, the vaccine is ready for subcutaneous injection.

Actions
A single 0.5 mL dose of Mencevax ACWY elicits a significant
antibody response against each of group A and group C
meningococci in over 90% of adolescents and young adults,
lasting at least 12 months.

Responses to W[135] and Y meningococci appear to be equally
good, but have been less well studied. Fewer data are available
on response rates in children 2 to 13 years, and antibody
persistence may be shortened, especially in the two to four year
age group.

Although the clinical efficacy of the A or C components of the
vaccine has been demonstrated, there are currently no data
available on the protective efficacy of the antibody response to
group W[135] and Y polysaccharides.

Indications
Active immunisation against meningococcal meningitis caused by
group A, group C, group W[135] and group Y meningococci in
adults and children over two years.

The vaccine may be used for subjects who are close contacts of
patients with disease caused by meningococci of groups A, C
W[135] and Y; for travellers to countries where the disease is
endemic or highly epidemic; and for controlling epidemics of
infection caused by groups A, C, W[135] and Y meningococci in
confined communities.

Mencevax ACWY is not recommended for use in infants and
children under two years of age as antigenicity of the vaccine is
low in this age group and antibodies persist for shorter duration.

Contraindications
As with all vaccines, Mencevax ACWY is contraindicated in
subjects with severe acute febrile illnesses. However, the
presence of a trivial infection does not contraindicate vaccination.

The multidose presentations should not be used in subjects with
known systemic hypersensitivity to phenol.

Warnings
The vaccine gives no protection against meningococcal meningitis
caused by meningococci belonging to groups other than A, C,
W[135] and Y.

If administered to subjects with impaired immune responses, the
vaccine may not induce an effective response.

Immune response to the vaccine may be impaired after acute
malaria.

The use of Mencevax ACWY may increase the meningococcal
carriage rates, especially for meningococcal groups not included
in the vaccine.

Precautions
Mencevax ACWY is for subcutaneous use only: do not
administer intravenously.

Appropriate precautions should be taken to prevent the
transmission of any infectious agent.

No information is available concerning the effects of drugs,
intercurrent illnesses or other vaccines on the response to the
administration of Mencevax ACWY.

As with all injectable vaccines, a solution of adrenaline 1 in 1,000
should always be readily available for immediate injection in case
of rare anaphylactic reactions. For this reason, the vaccinee
should remain under medical supervision for 30 minutes after
vaccination.

Use in pregnancy.
(Category B2)

There is no convincing evidence of risk to the fetus from
immunisation of pregnant women using an inactivated bacterial
vaccine. However, there are no studies on the effect of the
purified polysaccharides contained in Mencevax ACWY on the
fetus. Therefore, the vaccine should not be given to pregnant
women unless the benefits to the mother clearly outweigh any
risks to the fetus.

Use in lactation.
No information is available on the safety of the use of Mencevax
ACWY during lactation.

Adverse Reactions
Mencevax ACWY may induce local and systemic reactions;
local reactions occur in the majority of adults and include
erythema, induration, tenderness or pain at the site of injection
and local axillary lymphadenopathy. Febrile reactions (> 38 deg.
C) and chills, which are less common, may appear within hours
of vaccination and may persist for 24 to 48 hours or longer.
Upper respiratory tract illness, headache and malaise occur
occasionally. A transient local immediate weal and flare reaction
and hypersensitivity reactions including anaphylactoid reactions
may occur rarely. Local and systemic adverse reactions,especially
 febrile reactions, may be encountered more frequently
in children than in adults.

Dosage and Administration
Mencevax ACWY should be reconstituted only with the saline
solvent supplied by adding the entire contents of the supplied vial
of solvent to the vaccine vial. The reconstituted vaccine should be
inspected for any foreign particulate matter and/or colouration
prior to administration. In the event of either being observed,
discard the vaccine.

The reconstituted vaccine should be administered subcutaneously
with a sterile syringe and needle. One dose of vaccine is contained in 0.5 mL.

Data on the persistence of antibody response are limited and the
optimal time for revaccination is not known at present. It appears
likely that the antibody response will last for at least one year,
possibly longer.

Presentation
Vials, with sterile saline as solvent: monodose.

Storage
Store lyophilised vaccine in a refrigerator at 2 to 8 deg. C or in a
freezer. Shelf life: 2 years.
The solvent can be stored at ambient temperatures.
After reconstitution, the vaccine should be injected promptly or
kept in a refrigerator. If it is not used within eight hours, it should
be discarded because of the risk of contamination.

It is recommended to protect the reconstituted vaccine from direct sunlight.

When supplies of Mencevax ACWY are distributed from a central cold store,
it is good practice to arrange transport under refrigerated conditions, particularly
 in hot climates.

Poisons Schedule
S4.

 

清華診所的臉書facebook:
https://zh-tw.facebook.com/FamilyDoctors
https://www.facebook.com/FamilyDoctors

airtsuei 發表在 痞客邦 PIXNET 留言(0) 人氣()

新竹清華診所為新竹專門提供出國留學體檢的診所。電話:(03) 573 5050。歡迎出國學子先來電詢問。美國留學體檢推薦診所。

QuantiFERON®-TB Test

目前FDA核准一種診斷檢驗(QuantiFERON-TB GOLD,由Cellestis公司製造),可以偵測結核桿菌(TB)感染;這項血液測試使用合成TB胜月太來偵測干擾素γ,一種由免疫系統產生,對抗TB感染的蛋白質。  

核准案是根據臨床試驗結果,新檢驗的準確性(>99%)比結核菌素試驗更高;這項非主觀性檢驗主要可以提供一種有效、且經濟的TB篩檢方法,可以排除常見因非TB結核桿菌感染、以及避免之前接種卡介苗的交叉活性所造成的偽陽性結果。  

根據該公司的新聞稿,這項檢驗被預期可以取代結核菌素皮膚試驗,並且改善世界各地TB標準照護的水準。

美國疾病管制局為QuantiFERON®-TB Test提供的建議,請參考 Guidelines for using the QuantiFERON-TB test for diagnosis laten Mycombacterium tuberculosis infection http://www.cdc.gov/mmwR/preview/mmwrhtml/rr5202a2.htm

 

 

清華診所的臉書facebook:
https://zh-tw.facebook.com/FamilyDoctors
https://www.facebook.com/FamilyDoctors

airtsuei 發表在 痞客邦 PIXNET 留言(0) 人氣()

 新竹清華診所為新竹專門提供出國留學體檢的診所。電話:(03) 573 5050。歡迎出國學子先來電詢問。美國留學體檢推薦診所。

結核菌素皮膚試驗 (Tuberculosis Skin Test - PPD Skin Test)

Q:What is the tuberculosis skin test?
A:The tuberculosis skin test (also known as the tuberculin or PPD test) is a test used to determine if someone has developed an immune response to the bacterium that causes tuberculosis (TB). This response can occur if someone currently has TB or if they were exposed to it in the past. The tuberculin skin test is based on the fact that infection with M. tuberculosis produces a delayed-type hypersensitivity skin reaction to certain components of the bacterium. The components of the organism are contained in extracts of culture filtrates and are the core elements of the classic tuberculin PPD (also known as purified protein derivative). This PPD material is used for skin testing for tuberculosis. Reaction in the skin to tuberculin PPD begins when specialized immune cells, called T cells, which have been sensitized by prior infection, are recruited by the immune system to the skin site where they release chemical messengers called lymphokines. These lymphokines induce induration (a hard, raised area with clearly defined margins at and around the injection site) through local vasodilation edema, fibrin deposition, and recruitment of other inflammatory cells to the area.

Q:How is the tuberculosis skin test administered?
A:The standard recommended tuberculin test is administered by injecting 0.1mL of 5 TU (tuberculin units) PPD into the top layers of skin (intradermally, immediately under the surface of the skin) of the forearm. The use of a skin area that is free of lesions and away from veins is recommended. The injection is typically made using a one-quarter to one-half inch, 27-guage needle and a tuberculin syringe. The tuberculin PPD is injected just beneath the surface of the skin. A discrete, pale elevation of the skin (a wheal) 6 to 10 mm in diameter should be produced when the injection is done correctly. This wheal or "bleb" is generally quickly absorbed. If it is recognized that the first test was improperly administered, another test can be given at once, selecting a site several centimeters away from the original injection.

Q:What is the method of reading the tuberculosis skin test?
A:"Reading" the skin test means detecting a raised, thickened local area of skin reaction, referred to as induration. Induration is the key item to detect, not redness or bruising. Skin tests should be read between 48 and 72 hours after the injection when the size of the induration is maximal. Tests read after 72 hours tend to underestimate the size of the induration.

Interpretation of Skin Test Results
The basis of the reading of the skin test is the presence or absence and the amount of induration (localized swelling). The diameter of the induration should be measured transversely (i.e. perpendicular) to the long axis of the forearm and recorded in millimeters. The area of induration (palpable, raised, hardened area) around the site of injection is the reaction to tuberculin. Again, redness is not measured. A tuberculin reaction is classified as positive based on the diameter of the induration in conjunction with certain patient-specific risk factors. In a healthy person who is not immunocompromised, induration greater than or equal to 15mm is considered a positive skin test. If blisters are present (vesiculation), the test is also considered positive. In a person with underlying kidney disease, diabetes, or a healthcare worker, 10mm of induration is considered a positive skin test. 5 mm is considered a positive skin test result for patients who are immunocompromised, such as with rheumatoid arthritis patients and Crohn's disease patients. Induration of less than 2mm, without blistering, is considered a negative skin test.

http://www.cdc.gov/tb/publications/factsheets/testing/skintesting.htm

_________________________________________________________________________________________

Two-step Mantoux test

Some people who were previously infected with TB may have a negative reaction when tested years after infection, as the immune system response may gradually wane. This initial skin test, though negative, may stimulate (boost) the body's ability to react to tuberculin in future tests. Thus, a positive reaction to a subsequent test may be misinterpreted as a new infection, when in fact it is the result of the boosted reaction to an old infection.
Use two-step testing for initial skin testing of adults who will be retested periodically (e.g., health care workers). This ensures that any future positive tests can be interpreted as being caused by a new infection, rather than simply a reaction to an old infection.

  • Return to have first test read 48–72 hours after injection
  • If first test is positive, consider the person infected.
  • If first test is negative, give second test 1–3 weeks after first injection
  • Return to have second test read 48–72 hours after injection
  • If second test is positive, consider person previously infected
  • If second test is negative, consider person uninfected

A person who is diagnosed as "infected" on two-step testing is called a "tuberculin converter". The US recommendation that prior BCG-vaccination be ignored results in almost universal false diagnosis of tuberculosis infection in people who have had BCG (mostly foreign nationals). 

http://www.currytbcenter.ucsf.edu/abouttb/tbcontrol_faqs/2_how_is_two_step_tst_done.pdf

 

清華診所的臉書facebook:
https://zh-tw.facebook.com/FamilyDoctors
https://www.facebook.com/FamilyDoctors

airtsuei 發表在 痞客邦 PIXNET 留言(0) 人氣()

新竹清華診所為新竹專門提供留學體檢的診所。電話:(03) 573 5050。歡迎出國學子先來電詢問。美國留學體檢推薦診所。

Q:留學體檢需要什麼資料?

A:最常需要的就是記錄預防接種的黃卡。

留學體檢包括三大部份:

〈1〉檢驗:驗血/驗尿/結核菌素皮膚試驗、

〈2〉預防接種、

〈3〉身體檢查。

另外體檢表格有一部份不屬於醫師填寫的部份,這一部份需要學生自己完成。通常包括:過往的疾病史、是否有過敏性疾病、有那些藥物、食物過敏、目前服用什麼藥物、、、等等有關個人的健康資料。如果看不懂時,請携帶著,到時一 起詢問醫師。

預防接種記錄的黃卡上,會詳細地記錄你以前小時侯所接種的疫苗。應該說,記錄你入小學之前所有的預防接種記錄。至於入小學後的記錄有時無法記錄在黃卡上,事隔多年要再找,實在很難。

如果實在找不到黃卡,可以試試當地的衛生所,說不一定他們會保存以前預防接種的記錄。如果實在都找不到黃卡、衛生所也沒有記錄,只好跟醫師研究一下,看看如何補救。

註:記錄預防接種的黃卡現在已不在使用。現在新生兒出院時,醫院都會給父母親一本小冊子。這本小冊子叫「兒童健康手冊」,由衛生署國民健康局印行。裡面包括一些有關新生兒/幼兒健康衛生知識,及健康記錄,其中包括了預防接種記錄卡。所以,請謹慎保管這本小冊子。

不過,這幾年台灣預防接種做的非常好,其中一部份就是接種記錄的登錄與保存。但是時間較久遠前的資料,可能就不一定。

 

 

清華診所的臉書facebook:

https://www.facebook.com/FamilyDoctors

https://zh-tw.facebook.com/FamilyDoctors

airtsuei 發表在 痞客邦 PIXNET 留言(2) 人氣()

本診所提供  QuantiFERON , Tuberculosis Skin Test ( 結核菌素測驗, PPD Skin Test, Tuberculin Skin Test), 胸部X光檢查 (chest x-ray)

 

 

新竹清華診所為新竹專門提供留學體檢的診所。電話:(03) 573 5050。歡迎出國學子先來電詢問。美國留學體檢推薦診所。

Q:何時開始做準備留學體檢?

A:通常收到學校入學許可的套件內都會有入學必須填寫的資料,當然攸關留學體檢的表格也一併在內。

體檢表格內容,可以簡單地只有一、二頁,也可以複雜地多到十幾頁,更不用說裡面寫了一大堆看不懂的醫學名詞。

 

 

通常體檢表格包括:〈1〉驗血〈2〉預防接種〈3〉身體檢查。

醫師會先過目體檢表格,決定是否要驗血?那些疫苗要打?去那裡打?疫苗打的順序?這些可能會需要幾天,甚至幾週的時間。所以,最好是收到體檢表格後,儘快與醫師聯絡,以免時間太倉促。
最常見的處理方式就是拿去請教有經驗的朋友或同學,但最好的處理方式就是請教有關的醫療人員。

 

清華診所的臉書facebook:

https://www.facebook.com/FamilyDoctors

https://zh-tw.facebook.com/FamilyDoctors

 

 

airtsuei 發表在 痞客邦 PIXNET 留言(0) 人氣()